1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
689E4759180BE73AB002589B100248309
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medicals-road-map-for-social-media-success-rare-disease-omnichannel-integration-message-characteristics?opendocument
18
19opendocument
203.236.142.143
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Affairs Excellence

Medical’s Road Map for Social Media Success in Rare Disease Segment: Omnichannel Integration and Message Characteristics

ID: 5762


Features:

10 Info Graphics

11 Data Graphics

150+ Metrics

1 Narratives


Pages/Slides: 27


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Medical’s Road Map for Social Media Success in Rare Disease Segment: Omnichannel Integration and Message Characteristics”

STUDY OVERVIEW

Social media presents unique opportunities for Medical Affairs groups within Rare Disease organizations to overcome their challenges in developing meaningful connections with the right people. However, to thrive in this digital realm, it is paramount to adopt an omnichannel strategy that guarantees stakeholders a personalized and consistent experience across all platforms.


Best Practices, LLC conducted benchmarking research to develop a roadmap for Medical Affairs’ social media success in the Rare Disease Segment. This study establishes industry-leading standards around social media omnichannel integration, social media message characteristics, and performance measurement.

KEY TOPICS

  • Social Media Omnichannel Integration in Rare Disease
  • Social Media Message Characteristics and Performance Measurement
  • Social Media Innovation in Medical
  • Social Media Content and Sharing Trends in Rare Disease

KEY METRICS

  • Please indicate the platforms on which Medical performs different activities as part of the organization’s overall omnichannel engagement strategy
  • Please indicate the strategy used by Medical Affairs to handle misleading or non-compliant information on social media
  • Please indicate Medical group’s policy for sharing other content (e.g., retweeting other unaffiliated account’s tweets) on social media
  • Please indicate the types of social media content which originate from unaffiliated accounts and are shared/retweeted by Medical groups
  • Please indicate the organizational structure used by Medical Affairs to engage in omnichannel activities
  • Do Rare Disease organizations have in place a committee specifically tasked with reviewing social media content from a Medical compliance lens?
  • Please estimate the percentage of Medical Affairs group’s social media posts which are brand-oriented, molecule-oriented, and disease state-oriented
  • Please estimate the percentage of Medical Affairs group’s social media posts which are primarily graphic, contain a mix of both graphics and text, and are primarily text
  • Please indicate the effectiveness of each key performance indicator for measuring the success of Medical Affairs group’s social media engagements
  • Please specify the external stakeholders who have been engaged to contribute to the development of content for Medical Affairs group’s collaborative social media activities

SAMPLE KEY FINDINGS

  • Resharing Social Info: Nearly three quarters of Rare Disease Medical Groups prohibit resharing of social content from other information sources.
  • Message Orientation: Disease state-oriented (45%) and molecule-oriented (30%) messaging predominates the content shared by Rare Disease groups.

METHODOLOGY

Best Practices, LLC engaged 48 Medical leaders from 36 biopharma companies in this benchmarking research. For Rare Disease therapeutic area-specific insights, two segments were investigated in this study: Responses from 11 social media leaders at 8 Rare Disease organizations were analyzed against the rest of the total benchmark class.

Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Manufacturing; Consumer Products; Diagnostic; Communications; Medical; Biopharmaceutical; Health Care; Consulting


Companies Profiled:
AbbVie; Avidity Biosciences; AstraZeneca; Baxter Healthcare; Bayer; BIAL; Boehringer Ingelheim; Boston Scientific; Complete HealthVizion | An IPG Health Company; Dompé; DURECT Corporation; Eisai; Elevation Oncology; EMD Serono; Ethicon Endo-Surgery Inc.; Gossamer Bio; Grifols; Hoya Vision Care; Janssen; LEO Pharma; MedVal Scientific Information Services; Merck KGaA; Merck Sharp & Dohme; Merz Pharma; Merz Aesthetics; Myovant Sciences; Nobel Biocare; Novartis; Novartis Oncology; Novo Nordisk; PRECISIONscientia; Servier; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.